GlassScriptPhysician profile
Michael L Mawby
NPI 1720084114
$3,409.17
in general payments reported to CMS, 2019-2025
20 companies · $314 in 2025
The $314 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $180 · 2021: $699 · 2022: $664 · 2023: $905 · 2024: $156 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $984 · Education: $392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $983.54 |
| Education | $392.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $728.08 | 2019-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $646.06 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $627.55 | 2019-2024 | |
| Amgen INC. | $450.57 | 2019-2025 | Otezla, Enbrel, Avsola |
| Pfizer INC. | $215.02 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.75 | 2020-2023 | Spevigo, Cyltezo |
| Glaxosmithkline, LLC. | $106.24 | 2021-2023 | Benlysta, Nucala |
| E.R. Squibb & Sons, L.L.C. | $106.12 | 2021-2022 | |
| Horizon Therapeutics Plc | $91.41 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $63.41 | 2023 | Uptravi, Opsumit |
| Alexion Pharmaceuticals, INC. | $54.64 | 2020-2023 | Strensiq |
| Organon LLC | $39.16 | 2023 | Renflexis, Hadlima |
| Biogen, INC. | $24.79 | 2021 | |
| Radius Health, INC. | $22.39 | 2022 | |
| Genentech USA, INC. | $17.87 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $16.93 | 2021 | |
| Merck Sharp & Dohme LLC | $14.57 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Ucb, INC. | $12.44 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mawby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.